Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors

被引：90

作者：

Labrosse, B

Labernardière, JL

Dam, E

Trouplin, V

Skrabal, K

Clavel, F

Mammano, F

机构：

[1] Hop Bichat Claude Bernard, Unite Rech Antivirale, INSERM, U552, F-75018 Paris, France

[2] Viralliance SAS, Paris, France

来源：

JOURNAL OF VIROLOGY | 2003年 / 77卷 / 02期

关键词：

D O I：

10.1128/JVI.77.2.1610-1613.2003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Human immunodeficiency virus type 1 plasma viruses from 29 entry inhibitor-naive patients were characterized for their susceptibilities to T-20, AMD3100, and RANTES. A strikingly wide range of susceptibilities to T-20 was observed that was influenced by coreceptor usage but not by the susceptibilities of the viruses to inhibitors that target the chemokine receptors or by polymorphisms in the gp41 N helix.

引用

页码：1610 / 1613

页数：4

共 50 条

[1] Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors
Ray, Neelanjana
Harrison, Jessamina E.
Blackburn, Leslie A.
Martin, Jeffrey N.
Deeks, Steven G.
Doms, Robert W.
JOURNAL OF VIROLOGY, 2007, 81 (07) : 3240 - 3250
[2] env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors
Fikkert, V
Cherepanov, P
van Laethem, K
Hantson, A
Van Remoortel, B
Pannecouque, C
De Clercq, E
Debyser, Z
Vandamme, AM
Witvrouw, M
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (12) : 3954 - 3962
[3] Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?
Zhang, YJ
Moore, JP
JOURNAL OF VIROLOGY, 1999, 73 (04) : 3443 - 3448
[4] Escape from Human Immunodeficiency Virus Type 1 (HIV-1) Entry Inhibitors
De Feo, Christopher J.
Weiss, Carol D.
VIRUSES-BASEL, 2012, 4 (12): : 3859 - 3911
[5] Heterobiaryl Human Immunodeficiency Virus Entry Inhibitors
Lu, Rong-Jian
Tucker, John A.
Pickens, Jason
Ma, You-An
Zinevitch, Tatiana
Kirichenko, Olga
Konoplev, Vitalii
Kuznetsova, Svetlana
Sviridov, Sergey
Brahmachary, Enugurthi
Khasanov, Alisher
Mikel, Charles
Yang, Yang
Liu, Changhui
Wang, Jian
Freel, Stephanie
Fisher, Shelly
Sullivan, Alana
Zhou, Jiying
Stanfield-Oakley, Sherry
Baker, Brian
Sailstad, Jeff
Greenberg, Michael
Bolognesi, Dani
Bray, Brian
Koszalka, Barney
Jeffs, Peter
Jeffries, Cynthia
Chucholowski, Alexander
Sexton, Connie
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (14) : 4481 - 4487
[6] Herpes simplex virus type 2 infection increases human immunodeficiency virus type 1 entry into human primary macrophages
Elena Sartori
Arianna Calistri
Cristiano Salata
Claudia Del Vecchio
Giorgio Palù
Cristina Parolin
Virology Journal, 8
[7] Herpes simplex virus type 2 infection increases human immunodeficiency virus type 1 entry into human primary macrophages
Sartori, Elena
Calistri, Arianna
Salata, Cristiano
Del Vecchio, Claudia
Palu, Giorgio
Parolin, Cristina
VIROLOGY JOURNAL, 2011, 8
[8] Baseline susceptibility of primary HIV-2 to entry inhibitors
Borrego, Pedro
Calado, Rita
Marcelino, Jose M.
Bartolo, Ines
Rocha, Cheila
Cavaco-Silva, Patricia
Doroana, Manuela
Antunes, Francisco
Maltez, Fernando
Caixas, Umbelina
Barroso, Helena
Taveira, Nuno
ANTIVIRAL THERAPY, 2012, 17 (03) : 565 - 570
[9] Human immunodeficiency virus type 1 protease inhibitors
McDonald, CK
Kuritzkes, DR
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (09) : 951 - 959
[10] Betulinic acid derivatives: A new class of specific inhibitors of human immunodeficiency virus type 1 entry
Soler, F
Poujade, C
Evers, M
Carry, JC
Henin, Y
Bousseau, A
Huet, T
Pauwels, R
DeClercq, E
Mayaux, JF
LePecq, JB
Dereu, N
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (05) : 1069 - 1083

← 1 2 3 4 5 →